OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 18:05:49 24/05/2024 BST | ||
| 5.6 EUR / 5.63 EUR | +0.63% |
|
| Current month | +5.68% | ||
| 1 month | +27.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 5.6 | +0.36% |
| 23/05/24 | 5.58 | +0.54% |
| 22/05/24 | 5.55 | +1.83% |
| 21/05/24 | 5.45 | +3.61% |
| 20/05/24 | 5.26 | -0.94% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 05:07 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR8DU0 |
| ISIN | DE000HR8DU07 |
| Date issued | 05/07/2021 |
| Strike | 7,542 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.96 € |
|---|---|
| Lowest since issue | 1.57 € |
| Spread | 0.03 € |
| Spread % | 0.53% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.7
USD
Average target price
170.1
USD
Spread / Average Target
+7.88%
- Stock Market
- Certificates
- Certificat
